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Posaconazole (PCZ) is a clinically approved drug used predominantly for prophylaxis and 25 
salvage therapy of fungal infections. Here, we report its previously undescribed anti-human 26 
cytomegalovirus (HCMV) activity. By antiviral assays we demonstrated that PCZ, along 27 
with other azolic antifungals, has a broad anti-HCMV activity being active against different 28 
strains including low-passage clinical isolates and strains resistant to viral DNA polymerase 29 
inhibitors. Using a pharmacological approach, we identified the inhibition of human 30 
cytochrome P450 51 (hCYP51) or lanosterol 14α demethylase, a cellular target of 31 
posaconazole in infected cells, as a mechanism of anti-HCMV activity of the drug. Indeed, 32 
hCYP51 expression was stimulated upon HCMV infection and the inhibition of its 33 
enzymatic activity by either a lanosterol analog (VFV) or PCZ decreased HCMV yield and 34 
infectivity of released virus particles. Importantly, we observed that the activity of the first 35 
line anti-HCMV drug ganciclovir was tenfold boosted by PCZ and that GCV and PCZ act 36 
synergistically in inhibiting HCMV replication. Taken together, these findings suggest that 37 
this clinically approved drug deserves further investigation in the development of host-38 
directed antiviral strategies as a candidate anti-HCMV drug with a dual antimicrobial effect.  39 
 40 
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Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus that infects from 60% to 47 
nearly 80% of the human population worldwide and establishes a life-long persistence in the 48 
host characterized by sporadic reactivations in healthy individuals (1). HCMV is also a major 49 
opportunistic human pathogen, which causes life-threatening diseases in subjects with 50 
acquired or developmental immunodeficiency, such as transplant recipients or immune naïve 51 
fetuses. Indeed, HCMV causes deafness and neurological disorders in approximately 0.1% of 52 
congenital infections (2). Moreover, HCMV has been suggested as a cofactor of vascular 53 
diseases and immune senescence (3).  54 
To date, to prevent and treat HCMV infections, there is no vaccine available, and only a 55 
limited number of drugs are licensed for treatment: ganciclovir (GCV), its oral prodrug 56 
valganciclovir, foscarnet, acyclovir, its prodrug valacyclovir, cidofovir, and the recently 57 
approved letermovir (4,5). Currently, all the available anti-HCMV drugs target virus-58 
encoded proteins, i.e., the DNA polymerase and the terminase (5). The clinical use of these 59 
antivirals can have several drawbacks, such as an unfavorable safety profile characterized by 60 
severe acute or long-term toxicity and poor oral bioavailability (4). Moreover, no drug has 61 
been approved for the treatment of congenital infection (6) and the management of HCMV 62 
infections can be further complicated by the emergence of drug-resistant HCMV strains 63 
(7,8). For all these reasons, there is still a strong need to develop new, safe, and effective 64 
antiviral compounds, possibly endowed with a new mechanism of action.  65 
HCMV, like many other viruses, hijacks several cellular pathways and deeply alters many 66 
host physiological processes in order to replicate efficiently (9). Thus, the development of 67 
host-directed antiviral strategies could be an alternative or an additional approach to treat 68 
HCMV-associated diseases (10), as well as to overcome viral resistance issues. In this 69 
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regard, drug repurposing can represent a powerful strategy for the identification of host 70 
pathways and factors playing a role during viral replication (11-13). Based on this rationale, 71 
we followed this strategy to identify new compounds and targets for anti-HCMV 72 
intervention through a drug screening and follow-up studies that identified several novel 73 
HCMV inhibitors, including both approved drugs and natural compounds (12,14,15).  74 
Here, we report the discovery of the previously undescribed anti-HCMV activity of 75 
posaconazole (PCZ), a drug approved for the prophylaxis and salvage therapy of systemic 76 
fungal infections. Our study stems from the observation that drugs belonging to the class of 77 
azolic antifungals were identified in two previous independent drug repurposing screenings 78 
for inhibitors of HCMV replication (12,16,17). Starting from this observation, we initially 79 
evaluated the antiviral activity of a panel of azolic antifungals used both topically and for the 80 
treatment of invasive fungal infections. PCZ, which was not present in our original screened 81 
library, showed an interesting anti-HCMV activity, thus we decided to characterize further 82 
its antiviral mechanism. In the recent years, the antiviral properties of azolic antifungals has 83 
been an emerging topic and PCZ, together with itraconazole, was found to have activity 84 
against both positive-stranded RNA viruses, such as picornaviruses and flaviviruses 85 
(11,18,19), and against negative-stranded RNA viruses, such as Ebola virus and influenza 86 
virus (20,21).  87 
We investigated deeper the anti-HCMV activity of PCZ and found that its antiviral 88 
activity was related to its inhibitory activity against human cytochrome P450 51 (hCYP51, or 89 
lanosterol 14α demethylase). This enzyme is the most conserved cytochrome P450, as well 90 
as the only that catalyzes demethylation of lanosterol (22), being involved in both 91 
cholesterogenesis and synthesis of essential regulatory sterols during meiosis (23). Fungal 92 
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CYP51 is the target of PCZ and other antifungals in the treatment of mycosis, however our 93 
study suggests that human CYP51 is involved in the antiviral mechanism of PCZ against 94 
HCMV.  95 
Noteworthy, our data indicate that a combination of PCZ with GCV, the gold standard for 96 
anti-HCMV therapy, greatly potentiates the antiviral effect of the latter and is synergistic in 97 
inhibiting HCMV replication in infected cells. Thus, this study provides the rationale for a 98 





Anti-human cytomegalovirus activity of approved azolic antifungals. In a drug 104 
repurposing campaign, we previously identified a series of molecules endowed with anti-105 
HCMV activity, among which we noticed an overrepresentation of drugs belonging to the 106 
class of azolic antifungals (12). To extend this knowledge, a more complete panel of azolic 107 
antifungal drugs was analyzed for anti-HCMV activity (Table 1). As shown in Fig. 1A, in 108 
plaque reduction assays (PRA), posaconazole (PCZ) and ketoconazole (KTZ) showed a 109 
dose-dependent inhibitory effect on HCMV AD169 replication in HFF cells, similarly to 110 
what we previously reported for clotrimazole, econazole, and miconazole (12). On the other 111 
hand, under the same experimental conditions, fluconazole (FCZ), voriconazole (VCZ), and 112 
itraconazole (ITZ) did not exhibit significant anti-HCMV activity (Fig. 1B).  113 
Then, to exclude the possibility that the antiviral activity of PCZ might be due to 114 
cytotoxicity, its effect on the viability of uninfected HFFs cells was evaluated by MTT 115 
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assays. As reported in Table 1, we found that the antiviral activity of posaconazole was not 116 
due to cytotoxicity of the target cells, since a significant toxic effect was not observed at 117 
concentrations up to 250 µM. 118 
 Broad anti-HCMV activity of posaconazole and other antifungals. To investigate 119 
the spectrum of anti-HCMV activity of PCZ and of other antifungals, we repeated the 120 
antiviral assays with a panel of HCMV strains, including three different low passage-number 121 
clinical isolates (TB40-UL32-EGFP, VR1814, and 388438U). As reported in Figure 2, the 122 
anti-HCMV activity of PCZ was not dependent on the viral strain, since the EC50 values 123 
obtained with different HCMV strains were comparable (Table 2). Next, we evaluated the 124 
activity of PCZ against HCMV strains resistant to the available viral DNA polymerase 125 
inhibitors, as the emergence of drug resistance is an increasing cause of transplant failure 126 
associated with HCMV infections, in particular after prolonged antiviral therapy (24). PCZ 127 
fully inhibited the replication of viruses with mutations in UL54 gene conferring cross-128 
resistance to GCV and cidofovir or to foscarnet and acyclovir (strains 759rD100 and 129 
PFArD100, respectively, Table 2). Anti-HCMV activity against different strains was found 130 
also for MCZ and ECZ (Table 2), two other antifungal drugs emerged for anti-HCMV 131 
activity during the drug repurposing screening (12).  132 
Finally, the inhibitory activity of PCZ against HCMV resulted not cell type-133 
dependent, since the EC50 values measured for the TR strain in epithelial (EC50 = 4.2 µM) 134 
and endothelial (EC50 = 4.8 µM) cells were in line to that observed in fibroblasts (EC50 = 3.7 135 
µM) (Table 2). Moreover, since TR strain is naturally resistant to GCV and CDV, we 136 
obtained further evidence of the activity of PCZ against HCMV clinical strains resistant to 137 
DNA polymerase inhibitors. 138 
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 Taken together these results indicated that PCZ and other antifungals could have a 139 
mechanism of action different from that of anti-HCMV drugs targeting the viral DNA 140 
polymerase.    141 
Effects of PCZ treatment on HCMV yield. PCZ is routinely used as a systemic 142 
drug to prevent and treat fungal infections in immunosuppressed patients (25), thus, we 143 
decided to focus on this molecule, given that a potential dual antifungal and antiviral effect 144 
could be relevant in this clinical setting. To better characterize the anti-HCMV activity of 145 
PCZ, we also evaluated its effects on the production of virus progeny in a multi-cycle viral 146 
growth experiment. PCZ reduced the production of HCMV infectious progeny in a dose-147 
dependent manner as revealed by virus yield reduction assays (Table 3). In sum, we observed 148 
that treatment of HCMV-infected cells with PCZ after infection resulted in the inhibition of 149 
viral replication and progeny production.  150 
 Inhibition of human CYP51, a host target of posaconazole, correlates with anti-151 
HCMV activity. PCZ is known to interfere with different host pathways (26-29), among 152 
which there are cholesterol homeostasis and synthesis mediated by human CYP51, the rate-153 
limiting enzyme in late-stage cholesterogenesis (28-30). Thus, we exploited VFV, the most 154 
potent enzymatic inhibitor of hCYP51 identified so far (30), to investigate the involvement 155 
of hCYP51 during HCMV replication. Like other azolic compounds, VFV inhibits human 156 
CYP51 by binding in the enzyme active site and competing with the substrate lanosterol. In 157 
enzymatic assays in vitro, both VFV and PCZ inhibited the initial rate of lanosterol 158 
conversion catalyzed by purified hCYP51 with IC50 values of 0.5 and 8 µM, respectively 159 
(Fig. 3A and Table 3). This was not observed with VCZ (IC50 >100 µM), which served as a 160 
negative control in the enzymatic assays (Fig. 3A and Table 3). When tested by PRA, VFV 161 
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caused a dose-dependent inhibitory effect on HCMV replication (Fig. 3B), albeit with an 162 
EC50 value higher than that of PCZ (13.3 µM versus 3.3 µM). However, given the highly 163 
hydrophobic nature of VFV (LogP 5.4), we reasoned that VFV could be poorly soluble in the 164 
semi-solid medium used for PRAs, thus virus yield reduction assays with VFV were also 165 
performed. VFV showed indeed a strong and dose-dependent inhibitory effect on infectious 166 
virus production with an EC50 in the low-micromolar range (Fig. 3C and Table 3), thus 167 
suggesting that hCYP51 enzymatic activity is required for the production of infectious 168 
HCMV progeny.  169 
 HCMV infection activates hCYP51 expression. Since we observed that hCYP51 170 
enzymatic activity is required for HCMV replication, next we investigated whether its 171 
expression could be modulated during viral infection. Indeed, under normal conditions (i.e., 172 
cells grown in regular cholesterol-containing medium), the cholesterol biosynthetic pathway 173 
is not stimulated. To analyze the modulation of hCYP51 promoter upon HCMV infection, we 174 
transfected permissive U-373 MG cells with a plasmid encoding a reporter gene under the 175 
control of hCYP51 promoter and then infected them with HCMV. As shown in Fig. 4A, 176 
infection with HCMV activated hCYP51 promoter by about 40-fold. This upregulation was 177 
not observed when the transfected cells were infected with a UV-inactivated virus, which is 178 
able to bind and enter into the cells but not to express viral genes, arguing that de novo 179 
synthesized HCMV proteins are required for hCYP51 promoter activation (Fig. 4A). Upon 180 
infection of serum-fed HFFs, a ~2-fold increase in hCYP51 mRNA level was observed 181 
during the early phase of HCMV replication (Fig. 4B) and an accumulation of hCYP51 182 
protein throughout the virus cycle was accordingly detected by both Western blot (Fig. 4C 183 
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and Fig. S1) and immunofluorescence analysis in living cells (Fig. S2). Altogether, these 184 
data support the view that HCMV infection activates hCYP51 gene expression.  185 
Inhibition of hCYP51 enzyme during HCMV replication reduces the infectivity 186 
of viral progeny. As shown above, both VFV and PCZ inhibited hCYP51 enzyme, which 187 
catalyzes the rate-limiting step in late cholesterogenesis. Thus, treatment of HCMV-infected 188 
cells with these inhibitors should reduce de novo cholesterol synthesis during HCMV 189 
replication. The intracellular presence of cholesterol during HCMV infection and within the 190 
virus particle has been related to the infectivity of HCMV virions (31). We therefore 191 
hypothesized that the virus particles produced in cells treated with hCYP51 inhibitors might 192 
be less infective. To test this, we determined the particle-to-PFU ratio of cell-free HCMV 193 
released from infected HFF cells treated with PCZ, VFV, or DMSO as a control, assuming 194 
that each virus particle (infectious or defective) contained one genome. Treatment of 195 
HCMV-infected cells for 120 h with either PCZ or VFV significantly reduced both the 196 
number of HCMV genomes (Fig. 5A) and the infectivity of viral progeny, with a ~7-10-fold 197 
increase in particle-to-PFU ratio with respect to DMSO-treated infected cells (Fig. 5B). 198 
Altogether, the results from this section indicated that hCYP51 enzymatic activity is required 199 
in the context of productive HCMV replication and could contribute to the generation of 200 
infectious HCMV particles. 201 
GCV and PCZ act synergistically against HCMV replication in infected cells. 202 
We also tested by PRAs the antiviral efficacy of GCV in the absence or the presence of a 203 
dose of PCZ (3 µM) approximately equivalent to the mean concentration found in plasma by 204 
therapeutic drug monitoring of patients treated with PCZ (25). Noteworthy, in the presence 205 
of PCZ, GCV was ⁓10-fold more potent against HCMV than in the presence of the vehicle 206 
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DMSO (EC50 0.13 µM for the combination of GCV + PCZ versus 1.44 µM for GCV + 207 
DMSO, Fig. 6). Considering these results, we investigated further the effects of the 208 
combination of PCZ with GCV against the replication of HCMV AD169 by PRAs. As 209 
reported in Table 4, the combination of GCV and PCZ resulted in antiviral synergism at all 210 
drug combinations tested, since the Combination Index (CI) values calculated by applying 211 
the Chou & Talalay method (32) resulted all <0.9 (Table 4). We did not observe any evident 212 
cell cytotoxicity when the drugs were tested in combination, thus the synergistic effect on the 213 
reduction of viral plaques number was most likely the result of combining two drugs with 214 
different targets and mechanisms of action. Beside a reduction in the absolute number, we 215 
also observed a clear reduction in the size of the plaques when GCV was used in 216 
combination with PCZ. The calculated Dose Reduction Indexes are reported in Table S3. 217 
Although future trials will be required to validate this observation in a clinical setting, these 218 
results suggest that a combination of GCV and PCZ might represent a new therapeutic 219 




Our study stems from the observation of an overrepresentation of drugs belonging to 224 
the class of azolic antifungals among the molecules selected in a previous drug repurposing 225 
screening aimed at identifying new anti-HCMV compounds (12). Starting from this 226 
observation, we report for the first time that posaconazole, a drug already approved and used 227 
in both adult and pediatric immunosuppressed patients for prevention and as salvage therapy 228 
of fungal infections, is a potent inhibitor of HCMV replication in the low micromolar range.   229 
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By characterizing the anti-HCMV profile of PCZ, we found that upon treatment of 230 
infected cells with PCZ and VFV, two inhibitors of hCYP51 enzyme, the infectivity of the 231 
released HCMV particles is significantly reduced. Azolic antifungals have shown a 232 
polypharmacological profile mainly by affecting host cholesterol homeostasis and trafficking 233 
(26-29), in addition to be active against several unrelated viruses (11,18-21). In human cells, 234 
PCZ is known to interfere with several pathways, such as cholesterol trafficking from 235 
lysosomes by inhibiting the Niemann-Pick C1 protein transporter (26) and from ER by 236 
inhibiting oxysterol-binding protein (OSBP) cholesterol-shuttling protein (11,19), as well as 237 
cholesterogenesis by inhibiting hCYP51 enzyme (29,30). The inhibition of OSBP, the target 238 
of PCZ against single-stranded positive RNA viruses, might be however likely excluded as a 239 
possible mechanism of anti-HCMV activity of PCZ on the basis of the anti-HCMV activity 240 
exhibited also by imidazolic antifungals such as miconazole and econazole (Table 1 and 241 
Table 2), which do not bind OSBP (12,19).  242 
The reduced infectivity of HCMV particles released from PCZ-treated cells could be 243 
caused by the block of cholesterol trafficking and hCYP51 inhibition caused by the drug, 244 
leading to lower levels of available cholesterol. In fact, changes in the cholesterol uptake and 245 
efflux have been observed during HCMV infection (31,33), and it has been reported that 246 
virion cholesterol content is crucial for the infectivity of HCMV progeny (31). Later during 247 
infection, when appropriate levels of new cholesterol molecules could be required by HCMV 248 
to produce infectious virions, inhibition of hCYP51-mediated cholesterogenesis exerted by 249 
PCZ would thus have a detrimental effect on the infectivity of the released viral progeny. 250 
However, this hypothesis remains to be tested. Nonetheless, our data suggest a role of the 251 
late cholesterogenesis mediated by hCYP51 in the production of infectious HCMV virions. 252 
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Indeed, we found that HCMV induces hCYP51 expression during infection. Importantly, a 253 
functional role for hCYP51 in the context of productive HCMV infection was validated by a 254 
pharmacological approach with the enzymatic inhibitors VFV and PCZ. Furthermore, the 255 
observed decrease in virus yield and in infectivity of virus particles produced upon inhibition 256 
of hCYP51 enzymatic activity supports the view that new cholesterol molecules are indeed 257 
required for the generation of infectious virus particles. Accumulation of new cholesterol 258 
molecules might contribute in conferring appropriate membrane fluidity to the enlarged 259 
cytomegalic cell, in the organization of virion, or in the targeting and proper localization of 260 
viral proteins within the envelope or mature virus particle. Accordingly, in other virus 261 
models, both virion cholesterol content and effective cholesterogenesis have been reported to 262 
affect virus infectivity. Depletion of cholesterol during hepatitis B virus infection was shown 263 
to induce in fact a topologic change of the large envelope protein that renders the virus non-264 
infectious (34). Interestingly, also HIV-1 Nef protein induces hCYP51 expression to increase 265 
de novo cholesterol synthesis and enhance virions infectivity (35), and low levels of 266 
cholesterogenesis and cholesterol uptake have been related to a lower HIV trans-infection 267 
ability and a slower disease progression in vivo (36).  268 
Posaconazole peak levels (Cmax) in plasma of treated patients either under 269 
prophylaxis or treatment of invasive fungal infections depend on a series of different factors, 270 
among which there are the formulation, the posology, the diet, and of course the 271 
administered dose (37). During prophylaxis in patients at high risk of both fungal and 272 
HCMV infections and for therapeutic use in the treatment of mycosis, posaconazole peak 273 
levels are reported to be averagely 1.5-2 µg/ml, corresponding to 2.2-2.9 µM (41-42), and 274 
thus approximately equal to or below the EC50s that we found for posaconazole against 275 
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HCMV (Table 2). However, anti-HCMV activity for posaconazole within a clinically 276 
achievable range could be obtained either by synergistic combination with GCV or by 277 
developing a better formulation.  278 
We also observed that PCZ exerted anti-HCMV activity against both wild-type 279 
clinical isolates and drug-resistant viral strains in a cell-type independent manner. 280 
Importantly, we demonstrated that GCV and PCZ act synergistically in inhibiting HCMV 281 
replication in infected cells with a combination effect ranging from moderate to very strong 282 
synergism. The analysis of our data with Calcusyn software allowed the determination of the 283 
simulated Dose Reduction Index (DRI) for both GCV and PCZ. DRI estimates the extent to 284 
which GCV levels may be reduced when used in synergistic combination with PCZ to 285 
achieve effect levels compared with GCV used alone (32). For example, 90% inhibition of 286 
HCMV replication may be potentially obtained by reducing by 10- and 6-fold GCV and 287 
PCZ, respectively (Table S3), a condition that could be clinically achievable in treated 288 
patients. However, this simulation remains to be clinically tested in vivo. 289 
In conclusion, our study suggests that repurposing of posaconazole against HCMV 290 
both alone and in combination with GCV could foster the development of new antiviral 291 
strategies against this important viral pathogen, exploiting its dual antimicrobial activity, and 292 
contribute to understand how HCMV manipulates host pathways for a productive replication.  293 
 294 
 295 
MATERIALS AND METHODS 296 
 Compounds. Ganciclovir (GCV), foscarnet (FOS), and all the antifungal drugs were 297 
from Sigma-Aldrich. Cidofovir (CDV, Vistide) was from Gilead Sciences. VFV ((R)-N-(1-298 
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2-yl)benzamide) was synthesized at Vanderbilt University as described (43). For cellular 300 
assays, 100× stock of VFV was prepared in 25% dimethylsulfoxide (DMSO)/34% aqueous 301 
2-hydroxypropyl-β-cyclodextrin (v/v) purchased from Sigma.  302 
Cells and viruses. Human Foreskin Fibroblast (HFF), ARPE-19, and U-373 MG were all 303 
from the American Type Culture Collection (ATCC) and were cultured in Dulbecco 304 
modified Eagle’s medium (DMEM) (Life Technologies) supplemented with 10% fetal 305 
bovine serum (FBS, Life Technologies), 100 U/ml penicillin, and 100 µg/ml streptomycin 306 
sulfate (P/S, both from Life Technologies).  Human dermal microvascular endothelial cells 307 
(HMVECs) (CC-2543) were obtained from Clonetics and cultured in endothelial growth 308 
medium (EGM) (Clonetics). All cell cultures were maintained at 37°C in a humidified 309 
atmosphere supplemented with 5% CO2.  310 
HCMV (strain AD169) was purchased from the ATCC. HCMV TB40E-UL32-EGFP 311 
(kindly provided by C. Sinzger, University of Ulm, Germany) was previously described (44) 312 
as well as HCMV VR1814 (kindly provided by G. Gerna, IRCCS Policlinico San Matteo, 313 
Pavia, Italy) recovered from a cervical swab from a pregnant woman (45). HCMV 388438U 314 
clinical isolate was collected from a urine sample at the Microbiology and Virology Unity of 315 
Padua University Hospital (Italy) and was under passage 4 after primary isolation. HCMV 316 
strains resistant to antiviral drugs were obtained from the NIH AIDS Research and Reference 317 
Reagent Program (Rockville, MD) and previously described (46). HCMV TR was 318 
reconstituted by transfecting HFFs with the corresponding TR-BAC that was prepared from 319 
the TR clinical strain resistant to GCV and CDV and isolated from an ocular specimen (47). 320 
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Reconstitution of BAC-derived TR strain in fibroblasts generated infectious virus that 321 
retaines the ability to infect both endothelial and epithelial cells (48).  322 
Plaque reduction assays. Plaque reduction assays (PRAs) with HCMV were 323 
performed as previously described (49). Briefly, HFF, ARPE-19, and HMVEC cells were 324 
seeded at a density of 1.5 × 105 cells per well in 24-well plates. The next day, the cells were 325 
infected at 37°C with 80 Plaque Forming Unit (PFU) per well of the different viruses in 326 
serum-free DMEM. At 2 h p.i., the inocula were removed, cells were washed, and media 327 
containing various concentrations of each compound, 2% FBS, and 0.6% methylcellulose 328 
were added. After 10 days of incubation at 37°C, cell monolayers were fixed and stained 329 
with crystal violet, and viral plaques were counted. 330 
Cytotoxicity assays. The cytotoxicity of tested compounds was determined by the 3-331 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) method 332 
as described previously (50). 333 
Virus yield reduction assays. For virus yield reduction assays, HFF cells were 334 
plated at 2 × 104 cells per well in 96-well plates, incubated overnight, and infected the next 335 
day with HCMV AD169 at MOI = 0.1 PFU/cell. After virus adsorption for 2 h at 37°C, cells 336 
were washed and incubated with 0.2 ml of fresh medium containing 5% FBS in the absence 337 
or in the presence of test compounds. Plates were incubated for 5 days at 37°C, and then 338 
subjected to one cycle of freezing and thawing. Titres were determined by transferring 0.1 ml 339 
aliquots from each well to a fresh 96-well monolayer culture of HFF cells, followed by 1:5 340 
serial dilutions across the plate. Cultures were incubated for 7 days and at the end of 341 
incubation they were fixed and stained, and the numbers of plaques were determined. 342 
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Enzymatic assays in vitro. Recombinant human CYP51 and its redox partner 343 
NADPH-cytochrome P450 reductase (CPR) were expressed in Escherichia coli and purified 344 
as described previously (30). The standard reaction mixture contained 0.5 µM hCYP51 and 345 
1.0 µM CPR), 100 µM L-α-1,2-dilauroyl-snglycerophosphocholine, 0.4 mg/ml isocitrate 346 
dehydrogenase, and 25 mM sodium isocitrate in 50 mM potassium phosphate buffer (pH 7.2) 347 
containing 10% glycerol (v/v). After addition of the radiolabeled ([3-3H]) lanosterol (~4,000 348 
dpm/nmol; dissolved in 45% HPCD, w/v, final concentration 50 µM) and inhibitors 349 
(concentration range 0.1 - 20 µM), the mixture was preincubated for 30 s at 37 °C in a 350 
shaking water bath, the reaction was initiated by the addition of 100 µM NADPH and 351 
stopped by extraction of the sterols with 5 ml of ethyl acetate. The extracted sterols were 352 
dried, dissolved in methanol, and analyzed by a reversed-phase HPLC system (Waters) 353 
equipped with a β-RAM detector (INUS Systems) using a NovaPak octadecylsilane (C18) 354 
column and a linear gradient water/acetonitrile/methanol (1.0:4.5:4.5, v/v/v) (solvent A) to 355 
CH3OH (solvent B), increasing from 0 to 100% B for 30 min at a flow rate of 1.0 ml/min. 356 
The IC50 values were calculated using GraphPad Prism 6, with the percentage of lanosterol 357 
converted being plotted against inhibitor concentration and the curves fitted with non-linear 358 
regression (log(inhibitor) vs. normalized response - variable slope). 359 
Plasmids. The pCYP51-luc plasmid, which contains the −314/+343 human CYP51 360 
(hCYP51) gene promoter region upstream of the luciferase reporter gene was kindly 361 
provided by D. Rozman (Centre for Functional Genomics and Bio-Chips Institute of 362 
Biochemistry, Faculty of Medicine University of Ljubljana, Slovenia) and was previously 363 
described (51). pGAPDH-eGFP plasmid, which contains the promoter region of cellular 364 
 on A













GAPDH gene upstream of the enhanced Green Fluorescent Protein (eGFP) gene was 365 
previously described (41) and used as a control of transfection efficiency.  366 
Cell transfections and HCMV infection. For the transfection/infection experiments 367 
with HCMV, U-373 MG cells were grown on 24-well plates and co-transfected using 368 
calcium phosphate (Calcium Phosphate Transfection Kit, Sigma) with 1 µg of pCYP51-luc 369 
plasmid along with 0.2 µg of pGAPDH-eGFP plasmid as a control to normalize transfection 370 
efficiency. The next day, transfected cells were either mock-infected or infected with HCMV 371 
AD169 at MOI = 0.5 PFU/cell for 2 h and then incubated with 5% FBS-containing medium. 372 
At 48 h post-infection, luciferase activity as well as eGFP expression were measured. For all 373 
the experiments, the values were normalized by dividing the values obtained for luciferase 374 
(LU) by the fluorescence units (FU) obtained for eGFP expression and expressed as relative 375 
luciferase units (RLU). For UV-inactivation, a procedure previously described was followed 376 
(52). Briefly, HCMV diluted in serum-free DMEM was exposed for 8 min at a distance of 4 377 
cm under a UV-light (VL-6MC, 254 nM, 6w). Inactivation of the virus was assessed by 378 
immunofluorescence.  379 
Quantification of gene expression. HFF cells were seeded in 6-well plates at 6 × 105 380 
cells/well and incubated o/n at 37°C. In case of infection, the next day they were infected 381 
with HCMV AD169 at MOI = 1 PFU/cell for 2 h and then incubated with 5% FBS-382 
containing medium. Total RNA was extracted from samples collected at different times p.i. 383 
using a total RNA Purification Plus Kit (Norgen Biotek) according to the manufacturer’s 384 
protocol. cDNA was generated from RNA (2 µg) using random primers (Applied 385 
Biosystems) and M-MLV reverse transcriptase (Applied Biosystems). qPCR was performed 386 
with SYBR green reagent (Applied Biosystems) according to the manufacturer’s instructions 387 
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on a 7900 HT Fast Real-Time PCR System (Applied Biosystems) using primers for hCYP51, 388 
GAPDH, and HCMV UL54 genes (sequences reported in Table S1). The relative changes in 389 
gene expression were calculated by means of the ΔΔCt method (53) using GAPDH to 390 
normalize data. 391 
Western Blot. For the analysis by Western blot of the induction hCYP51 during 392 
HCMV infection, subconfluent HFF cells in 6-well plates were infected with HCMV AD169 393 
at a MOI = 0.5 PFU/cell. Whole-cell protein extracts were prepared at different times as 394 
previously described (12) and then analyzed by Western blot with different antibodies listed 395 
in Table S2. Immunocomplexes were detected with the appropriate secondary anti-396 
immunoglobulin Abs conjugated to horseradish peroxidase (Life Technologies). 397 
Densitometry analysis was performed with ImageJ software (https://imagej.nih.gov/ij/). 398 
Immunofluorescence and confocal microscopy analysis. For confocal laser-399 
scanning microscopy analysis, HFFs were infected with HCMV AD169 at an MOI = 0.25 400 
PFU/cell. At different times p.i., cells were fixed with 4% paraformaldehyde in PBS 1× for 401 
15 min at room temperature and then permeabilized with 0.1% Triton X-100 in PBS for 20 402 
min at RT. After washing extensively with PBS, cells were incubated first with 4% FBS in 403 
PBS for 1 h at room temperature and then with different primary antibodies (listed in Table 404 
S2) diluted in FBS 4% in PBS 1× for 1 h at 37°C under shaking. Cells were then washed 405 
extensively with 4% FBS in PBS 1× and incubated with secondary fluorochrome-conjugated 406 
antibodies (listed in Table S2) for 1 h at 37 °C. Nuclei were stained by incubation for 20 min 407 
with Draq5 (1:8,000 in PBS 1×). Cells were imaged using a Nikon Eclipse Ti-E microscope. 408 
Particle-to-PFU ratio determination. To determine the particle-to-PFU ratio of 409 
HCMV produced in the presence of test compounds, HFFs were seeded at 2 × 104 cells per 410 
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well in 96-well plates, incubated overnight, and infected the next day with HCMV AD169 at 411 
MOI = 0.5 PFU/cell. After virus adsorption for 2 h at 37°C, cells were washed and incubated 412 
with 0.2 ml of fresh medium containing 5% FBS in the presence or in the absence of test 413 
compounds. Plates were incubated for 5 days at 37°C. At the end of the incubation, 0.05 ml 414 
of supernatants were used to determine the number of virus particles that were produced 415 
under the different experimental conditions, while 0.05 ml were titrated on fresh monolayers 416 
of HFF cells as previously described, to determine the number of PFUs present in the same 417 
volume of supernatant. For virus particles determination, 0.05 ml of supernatants were 418 
incubated with 0.2% SDS and proteinase K for 1 h at 56°C and then for 15 min at 95°C to 419 
inactivate proteinase K. Then, viral DNA was extracted with DNA purification kit (Promega) 420 
and quantified by qPCR as described below. The particle-to-PFU ratio was determined by 421 
dividing the number of HCMV genomes by the number of PFU determined in the same 422 
volume of supernatant derived from the same sample.  423 
Quantification of viral genomes. To quantify the HCMV genomes in 0.05 ml of 424 
supernatants derived from the different samples collected at 120 h p.i., quantitative Real-425 
Time PCR (qPCR) was performed as previously described (46). The number of viral 426 
genomes was normalized to the cellular β-globin gene copies. The sequences of the 427 
oligonucleotides used are listed in Table S1. 428 
Drug combination studies. To evaluate the combined effects of PCZ and GCV on 429 
HCMV AD169 replication, plaque reduction assays were performed as described above 430 
using 0.25x, 0.50x, 1x, 2x, and 4x EC50 for each combination of PCZ and GCV at equipotent 431 
ratio. The 2-drug combination effects were assessed using the Chou-Talalay method (32) 432 
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based on mass-action law based dynamic theory computed in the CalcuSyn software version 433 
2.0 (Biosoft, Cambridge, UK).  434 
Statistical analysis. All statistical analyses were performed using GraphPad Prism 435 




SUPPLEMENTAL MATERIAL 440 
 Supplemental material to this article may be found at journal website. 441 
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 633 
FIGURE LEGENDS 634 
FIG 1 Susceptibility of HCMV to approved azolic antifungals. Plaque reduction assays 635 
were performed in HFF infected with HCMV and treated with different doses (from 0.1 to 25 636 
µM) of the indicated test compounds or GCV as a control. (A) Dose-dependent inhibition of 637 
HCMV AD169 replication by PCZ and KTZ. (B) Absence of significant inhibition of 638 
HCMV AD169 replication by FCZ, ITZ, and VCZ. (ITZ could be tested only up to 10 µM 639 
due to solubility issues). Graph represents mean ± SD of n ≥ 3 independent experiments in 640 
duplicate. 641 
 on A













FIG 2 Dose-dependent inhibition of the replication of indicated HCMV strains by 642 
posaconazole. Plaque reduction assays were performed in HFF infected with the indicated 643 
HCMV strains and treated with different doses (from 0.1 to 25 µM) of PCZ. Graphs 644 
represents mean ± SD of n = 3 independent experiments in duplicate.  645 
FIG 3 Inhibition of host hCYP51 affects HCMV replication.  (A) Inhibition of enzymatic 646 
activity of purified hCYP51 by VFV, PCZ, and VCZ (2 min reaction). Graph represents the 647 
mean ± SD of n = 3 independent experiments in duplicate. (B) Plaque reduction assays were 648 
performed in HFF infected with HCMV AD169 and treated with different doses (from 0.1 to 649 
25 µM) of hCYP51 inhibitor VFV. Graphs represent the mean ± SD of n ≥ 3 independent 650 
experiments in duplicate. (C) Dose-dependent inhibition by VFV of virus progeny 651 
production in HCMV-infected HFFs as determined by virus yield reduction assays. Graph 652 
represents the mean ± SD of n = 4 independent experiments in duplicate.  653 
FIG 4 hCYP51 expression is activated during HCMV infection. (A) Activation of 654 
hCYP51 promoter in U-373 MG cells mock-infected or infected with either HCMV AD169 655 
or UV-inactivated HCMV. Reported data are expressed as Relative Luciferase Units 656 
(LU/FU, RLU), which are the luciferase units normalized to the fluorescence units derived 657 
from the expression of the co-transfected eGFP reporter gene. Graph represents the mean ± 658 
SD of n = 3 independent experiments in duplicate. Data were analyzed by a one-way 659 
ANOVA followed by Tukey’s multiple comparison tests. ***p≤0.0001; ****p<0.0001. (B) 660 
Analysis of hCYP51 mRNA levels upon HCMV infection of HFF cells determined by qPCR 661 
at the indicated times. The mRNA levels of UL54 were detected as a control for the 662 
progression of the infection at 24 and 48 h p.i. mRNA levels were normalized to cellular 663 
GAPDH and gene expression was reported as relative quantification (RQ) compared to 664 
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calibrator sample (mock-infected cells for hCYP51 and HCMV-infected cells at 24 h p.i. for 665 
UL54). Graph represents the mean ± SD of n = 3 independent experiments in duplicate. (C) 666 
Analysis of hCYP51 and viral proteins expression during HCMV replication. Host hCYP51 667 
protein and viral IE antigens (IEA) were detected by Western blot both in mock-infected 668 
HFFs (M) and in HFFs infected with HCMV at an MOI = 0.5 PFU/cell at the indicated h p.i. 669 
Detection of host β-actin was used as a loading control. Molecular weights in kDalton are 670 
indicated on the left. Image of a representative experiment is showed.  671 
FIG 5 Effects of hCYP51 enzymatic activity inhibition on HCMV replication and 672 
infectivity. (A) Pharmacological inhibition of hCYP51 reduces the number of HCMV 673 
genomes. HFF cells infected with HCMV at MOI = 0.5 PFU/cell were treated with 10 µM 674 
PCZ or VFV, or 0.1% DMSO as a control for 120 h. HCMV genome copies in the 675 
supernatant of each sample were then determined by qPCR. Graph represents the mean ± SD 676 
of n = 3 independent experiments in quadruplicate. Data were analyzed by a one-way 677 
ANOVA followed by Dunnett’s multiple comparison test. ***p<0.001; **p<0.005 compared 678 
to control (DMSO-treated, infected sample). (B) Pharmacological inhibition of hCYP51 679 
reduces the infectivity of viral particles. Particle-to-PFU ratios were obtained by dividing the 680 
number of HCMV particles collected from supernatants derived from HFFs infected at MOI 681 
= 0.5 PFU/cell and treated with test compounds (determined by qPCR) by the viral titers 682 
obtained in the same sample volume (determined by titration on fresh monolayers). Graph 683 
represents the mean ± SD of n = 3 independent experiments in quadruplicate. Data were 684 
analyzed by a one-way ANOVA followed by Dunnett’s multiple comparison tests. *p<0.05; 685 
**p<0.005, compared to control (DMSO-treated, infected sample). 686 
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FIG 6 Therapeutic dose of posaconazole enhances anti-HCMV activity of ganciclovir. 687 
Antiviral efficacy of GCV against HCMV AD169 in the absence (+ DMSO) or the presence 688 
(+ PCZ) of 3 µM PCZ as determined by PRA. Graph represents the mean ± SD of n ≥ 3 689 





















Table 1. Antiviral activity of antifungal drugs against HCMV AD169 697 
 698 
Compound (Abbreviation) EC50b (µM) CC50
c (µM) SId 
Clotrimazole (CTZ)a 0.8 ± 0.6 40 ± 28 50 
Econazole (ECZ)a 5.7 ± 1.7 85 ± 13 17 
Fluconazole (FCZ) > 25 >250 >10 
Itraconazole (ITZ) >10 N.D. N.D. 
Ketoconazole (KTZ) 14.4 ± 4.6 116 ± 6 8 
Miconazole (MCZ)a 3.2 ± 0.8 55 ± 16 17 
Posaconazole (PCZ) 3.3 ± 0.5 >250  >76 
Voriconazole (VCZ) > 25 > 250 >10 
Ganciclovir (GCV) 2.3 ± 0.6 >500 >217 
a    Reported in Reference 12. 699 
b 50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as 700 
determined by PRAs against HCMV AD169 in HFF cells. Reported values represent the means ± SD of data 701 
derived from n ≥ 3 independent experiments in duplicate. GCV was included as a positive control. 702 
c Compound concentration that produces 50% of cytotoxicity, as determined by MTT assays in HFF cells. 703 
Reported values represent the means ± SD of data derived from two independent experiments in duplicate.   704 
d SI, Selectivity Index (determined as the ratio between CC50 and EC50).   705 






































Table 2. Antiviral activity of antifungal drugs against different HCMV strains in 730 
different cell types 731 
 732 
 733 
HCMV strain Cell type Antiviral activity EC50a (µM)  
 ECZ MCZ PCZ Controlb 
TB40-UL32-EGFP HFF 4.5 ± 0.7 3.8 ± 0.4 3.5 ± 1.8 3.5 ± 0.7 
VR1814 HFF 3.9 ± 2.1 4.3 ± 1.1 3.5 ± 0.7 2.3 ± 1.3 
388438U HFF N.D. N.D. 3.2 ± 0.4 3.2 ± 0.8 
759rD100 HFF 4.3 ± 1.1 4.5 ± 1.8 2.6 ± 1.2 75 ± 12 
GDGrP53 HFF 3.4 ± 0.9 2.6 ± 0.3 3.5 ± 1.1 1.9 ± 1.8 
PFArD100 HFF 4.2 ± 0.1 3.7 ± 0.6 4.8 ± 1.5 250 ± 18 
TR HFF N.D. N.D. 3.7 ± 1.3  N.D. 
TR ARPE-19 N.D. N.D. 4.2 ± 1.8 N.D. 
TR HMVEC N.D. N.D. 4.8 ± 2.0 N.D. 
a 50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as 734 
determined by PRAs in HFFs, and for TR strain also in epithelial (ARPE-19) and endothelial (HMVECs) cells. 735 
Reported values represent the means ± SD of data derived from n ≥ 3 independent experiments in duplicate. 736 
b GCV was used as a control for all strains except for PFArD100, for which FOS was used.  737 




































Table 3. Activity of posaconazole and VFV in virus yield reduction assays and in 760 
enzymatic assays in vitro 761 
 762 
 763 
Compound Antiviral Activity (μM) Inhibitory Activity (µM) 
EC50a EC90b IC50
c 
PCZ 2.2 ± 1.1 7.1 ± 1.1 8.0 ± 2.5 
VFV 1.2 ± 0.9 10.1 ± 1.3 0.5 ± 0.2 
VCZ N.D. N.D. >100 
a 50% Effective Concentration, the compound concentration that inhibits 50% of virus yield, as determined by 764 
titration in HFF cells. Reported values represent the means ± SD of data derived from n = 4 independent 765 
experiments in duplicate. 766 
b 90% Effective Concentration, the compound concentration that inhibits 90% of virus yield, as determined by 767 
titration in HFF cells. Reported values represent the means ± SD of data derived from n = 4 independent 768 
experiments in duplicate. 769 
c 50% Inhibitory Concentration, the compound concentration that causes a 50% decrease in the rate of 770 
lanosterol conversion, as determined by reconstitution of the hCYP51 activity in vitro, 2 min reaction. Reported 771 
values represent the means ± SD of data derived from n = 3 independent experiments in duplicate and 772 
calculated using GraphPad Prism 6.0 (dose-response –inhibition). 773 
































at equipotent ratio (fold of EC50a) 
CIb Drug Combination effectc 
0.25 0.625 ± 0.169 Synergism 
0.5 0.780 ± 0.031 Moderate synergism 
1 0.353 ± 0.278 Synergism 
2 0.075 ± 0.039 Very strong synergism 
4 0.064 ± 0.042 Very strong synergism 
 791 
a Fold of 50% Effective Concentration for GCV/PCZ yielding an equipotent concentration ratio between the 792 
two combined drugs. The EC50 values was determined by PRAs against HCMV AD169 in HFF cells for each 793 
drug alone or in combination at concentrations starting from 4-fold to 0.25-fold the equipotent ratio of the drugs 794 
considering ratio 1:1.33, approximated values from Table 1. 795 
b Combination Index, obtained by computational analysis with Calcusyn software. Reported values represent 796 
means ± SD of data derived from n = 3 independent experiments in triplicate. 797 
c Drug combination effect defined as: very strong synergism for CI<0.1; strong synergism for 0.1<CI<0.3; 798 
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